

# Natalizumab Takes Crohn's Remission Past 2 Years

BY MITCHEL L. ZOLER  
Philadelphia Bureau

BERLIN — Treatment with natalizumab maintained remission in selected patients with severe Crohn's disease for more than 2 years, in an open-label extension study with 87 patients.

"The data show that if a patient [with Crohn's disease] goes into initial remission [on natalizumab treatment], the patient is likely to maintain the remission," often without the need for steroid treatment, Dr. Remo Panaccione said at the 14th United European Gastroenterology Week.

Of the 905 patients with severely active Crohn's disease who entered the study, about 30% achieved and maintained remission over the 27-month study period. But natalizumab's efficacy was greater in the

**'If a patient [who has Crohn's disease] goes into initial remission [on natalizumab treatment], the patient is likely to maintain the remission.'**

subset of patients who responded initially. In the 87 patients who achieved and maintained remission on natalizumab during the initial 15 months of therapy, 86% remained in remission during the next 12 months of treatment,

said Dr. Panaccione, a gastroenterologist at the University of Calgary (Alta.).

Natalizumab is a humanized monoclonal antibody that inhibits leukocyte adhesion and migration into inflamed tissue. The new study used patients who had been enrolled in the first and second rounds of the International Efficacy of Natalizumab in Active Crohn's Therapy (ENACT) trial, ENACT-1 and ENACT-2. Both studies, as well as the subsequent open-label extension, were sponsored by Biogen Idec and Elan Pharmaceuticals, which produce and market natalizumab (Tysabri).

The drug was off the U.S. market for more than a year, starting in early 2005, because a fatal case of progressive multifocal leukoencephalopathy was linked to its use. But marketing resumed earlier this year with the indication of monotherapy for relapsing multiple sclerosis. Under the revised approval, natalizumab prescribers must first register with Elan.

In the first ENACT study, 56% of Crohn's disease patients responded, and 37% had remission after three doses of 300 mg natalizumab, given by an intravenous infusion every 4 weeks. These rates were slightly above those for the placebo group. The second study began with 339 of the natalizumab-treated patients from the first study who had responded to the drug. They were randomized to placebo or ongoing natalizumab infusions, every 4 weeks, for another 48 weeks.

The primary end point was the rate of a sustained response after 36 weeks of treatment, which was 61% in patients treated with natalizumab and 28% in the placebo group, a statistically significant difference. Remission rates at week 36 were

44% with natalizumab treatment and 26% without, also a significant difference (N. Engl. J. Med. 2005;353:1912-25).

The current study included 87 patients who completed ENACT-2 and were in remission 15 months after they started their natalizumab regimen. After treatment with another six doses over the next 24 weeks, 81 patients (93%) remained in remission. After the next six doses, or 48 weeks after the new study began, 75 patients (86%) remained in remission.

Most of the patients in remission were maintained without treatment with a corticosteroid. The average Crohn's Disease Activity Index score for the 87 patients remained at less than 90. Included in the extended-treatment group were 22 patients who were previously treated with a biologic drug that cut the activity of tumor necrosis factor- $\alpha$  (such as infliximab); 11 of these patients also failed prior treatment with an anti-TNF drug. These subgroups maintained their remission on natalizumab about

as well as the overall study group did.

In these 87 patients, the overall safety profile was good. There was an 18% rate of drug-attributable, serious adverse effects, and five patients (6%) stopped treatment because of an adverse effect. The most common adverse effects were nasopharyngeal (21%), headache (20%), and exacerbation of Crohn's disease (15%). Four patients had serious infections. None developed an immune reaction to natalizumab. ■



**AtHOME**

thanks to ARICEPT®'s overall effectiveness

**ARICEPT helps patients  
be more like themselves longer™**

- Helped keep patients in the community for more than 5 years<sup>1\*</sup>
- Is proven effective in cognition, function, and behavior<sup>2,5</sup>
- Caregivers spend less time assisting patients with everyday activities<sup>6</sup>
- Established safety and tolerability

\* Results from an observational follow-up of nursing home placement in mild to moderate AD patients (MMSE 10-26) previously enrolled in 1 of 3 randomized, double-blind, placebo-controlled trials with open-label extension phases.

† As with all studies of this type, results may be attributable to various factors. ARICEPT treatment was one such factor.

ARICEPT is indicated for mild to moderate dementia of the Alzheimer's type.

The most common adverse events in clinical trials with ARICEPT were nausea, diarrhea, insomnia, vomiting, muscle cramps, fatigue, and anorexia. In clinical trials, syncopal episodes have been reported (2% for ARICEPT versus 1% for placebo). Cholinesterase inhibitors have the potential to increase gastric acid secretion. Patients at risk for developing ulcers, including those receiving concurrent NSAIDs, should be monitored closely for gastrointestinal bleeding.

Clinical studies of ARICEPT have shown no increase, relative to placebo, in the incidence of either peptic ulcer disease or gastrointestinal bleeding.

Please see brief summary of prescribing information on adjacent page.

**ARICEPT**®  
(donepezil HCl)

ONCE-A-DAY  
**ODT**™  
Orally Disintegrating  
Tablets (5-MG and 10-MG)

ONCE-A-DAY  
**ARICEPT**®  
(donepezil HCl)  
5-MG AND 10-MG TABLETS

References: 1. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. *J Am Geriatr Soc.* 2003;51:937-944. 2. Winblad B, Engedal K, Soiminen H, et al, and the Donepezil Nordic Study Group. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. *Neurology.* 2001;57:489-495. 3. Mohs RC, Doody RS, Morris JC, et al, for the "312" Study Group. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. *Neurology.* 2001;57:481-488. 4. Rogers SL, Doody RS, Mohs RC, Friedhoff LT, and the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. *Arch Intern Med.* 1998;158:1021-1031. 5. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, and the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. *Neurology.* 1998;50:136-145. 6. Feldman H, Gauthier S, Hecker J, et al, and The Donepezil MSAD Study Investigators Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. *J Am Geriatr Soc.* 2003;51:737-744. AR273436A